pLXSN human KIT V654A + D816Y
OHSU # 1658-E
This line was created by ENU-mutagenesis of BaF3 pLXSN KIT D816Y cell line and drug selection. The V654A mutation is associated with imatinib-resistance in GIST. This cell line expresses high levels of activated KIT. In addition to the engineered D816Y mutation, the cells also acquired the following mutations due to retrovirus recombination events: N587S and deletion of amino acids 931-961. These secondary events do not appear to alter the kinase properties of KIT or alter the pattern of D816Y sensitivity/resistance to kinase inhibitors. This cell line is strongly resistant to imatinib.
- Michael Heinrich, SM.Knight Hem/Onc Admin
For more information, contact:
Technology Development Manager